公开(公告)号：WO2004003218A3

公开(公告)日：2004-02-26

申请号：PCT/US0319358

申请日：2003-06-18

Applicant: ISIS PHARMACEUTICALS INC ,  DOBIE KENNETH W

Inventor： DOBIE KENNETH W

IPC: A61K38/00 ,  C12N5/02 ,  C12N15/113 ,  C12Q1/68 ,  A01N43/04 ,  A61K31/07 ,  C07H21/04

CPC classification number: C12N15/113 ,  A61K38/00 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  Y02P20/582 ,  C12N2310/3525

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of hypothetical protein LOC51249. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding hypothetical protein LOC51249. Methods of using these compounds for modulation of hypothetical protein LOC51249 expression and for treatment of diseases associated with expression of hypothetical protein LOC51249 are provided.

Abstract translation: 提供反义化合物，组合物和方法用于调节假定蛋白LOC51249的表达。 组合物包含靶向编码假想蛋白质LOC51249的核酸的反义化合物，特别是反义寡核苷酸。 提供了使用这些化合物调节假想蛋白质LOC51249表达和治疗与假想蛋白质LOC51249表达相关疾病的方法。

公开(公告)号：WO03052072A2

公开(公告)日：2003-06-26

申请号：PCT/US0240083

申请日：2002-12-13

Applicant: ISIS PHARMACEUTICALS INC ,  DOBIE KENNETH W ,  ROACH MARK P

Inventor： DOBIE KENNETH W ,  ROACH MARK P

IPC: A61K38/00 ,  C12N15/113 ,  C12N

CPC classification number: C12N15/1138 ,  A61K38/00 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  Y02P20/582 ,  C12N2310/3525

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of estrogen receptor alpha. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding estrogen receptor alpha. Methods of using these compounds for modulation of estrogen receptor alpha expression and for treatment of diseases associated with expression of estrogen receptor alpha are provided.

Abstract translation: 提供反义化合物，组合物和方法用于调节雌激素受体α的表达。 组合物包含靶向编码雌激素受体α的核酸的反义化合物，特别是反义寡核苷酸。 提供了使用这些化合物调节雌激素受体α表达和治疗与雌激素受体α表达相关的疾病的方法。

公开(公告)号：WO2006110775A3

公开(公告)日：2010-07-01

申请号：PCT/US2006013536

申请日：2006-04-10

Applicant: ISIS PHARMACEUTICALS INC ,  BHANOT SANJAY ,  MONIA BRETT P ,  GEISLER JOHN ,  MCKAY ROBERT ,  DOBIE KENNETH W

Inventor： BHANOT SANJAY ,  MONIA BRETT P ,  GEISLER JOHN ,  MCKAY ROBERT ,  DOBIE KENNETH W

IPC: C07H21/02 ,  A61K31/7088

CPC classification number: C12N15/1137 ,  A61K31/202 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/3521

Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of ACCl or ACC2 or both in a cell, tissue or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.

Abstract translation: 本文公开了用于调节细胞，组织或动物中ACC1或ACC2或两者的表达的化合物，组合物和方法。 还提供了所公开的化合物和组合物在制备用于治疗疾病和病症的药物中的用途。

公开(公告)号：WO2008011473A3

公开(公告)日：2008-10-30

申请号：PCT/US2007073799

申请日：2007-07-18

Applicant: ISIS PHARMACEUTICALS INC ,  DOBIE KENNETH W ,  DEAN NICHOLAS M ,  BENNETT C FRANK

Inventor： DOBIE KENNETH W ,  DEAN NICHOLAS M ,  BENNETT C FRANK

IPC: C07H21/04

CPC classification number: C12N15/1135 ,  C12N2310/11

Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of HBXIP in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.

Abstract translation: 本文公开了用于调节细胞，组织或动物中HBXIP表达的化合物，组合物和方法。 还提供了目标验证的方法。 还提供了公开的化合物和组合物在制备用于治疗疾病和病症的药物中的用途。

公开(公告)号：WO2007137301A8

公开(公告)日：2008-03-06

申请号：PCT/US2007069587

申请日：2007-05-23

Applicant: ISIS PHARMACEUTICALS INC ,  BHANOT SANJAY ,  DOBIE KENNETH W ,  MURRAY SUSAN F

Inventor： BHANOT SANJAY ,  DOBIE KENNETH W ,  MURRAY SUSAN F

IPC: A61K31/70 ,  C07H21/02 ,  C07H21/04 ,  C12N5/00 ,  C12Q1/68

CPC classification number: C12N15/113 ,  C12N2310/11 ,  C12N2310/322 ,  C12N2310/341 ,  C12N2310/3525

Abstract: Disclosed herein are compounds, compositions, and methods for modulating the expression of ChREBP in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and conditions.

Abstract translation: 本文公开了用于调节细胞，组织或动物中ChREBP表达的化合物，组合物和方法。 还提供了目标验证的方法。 还提供了公开的化合物和组合物在制造用于治疗疾病和病症的药物中的用途。

公开(公告)号：WO2005049630A3

公开(公告)日：2006-03-02

申请号：PCT/US2004038545

申请日：2004-11-17

Applicant: ISIS PHARMACEUTICALS INC ,  DOBIE KENNETH W ,  KOLLER ERICH ,  JAIN RAVI

Inventor： DOBIE KENNETH W ,  KOLLER ERICH ,  JAIN RAVI

IPC: A61K48/00 ,  C12N9/14 ,  C12N15/113 ,  C12Q1/68 ,  A01N43/04 ,  A61K31/07 ,  C07H21/04

CPC classification number: C12N15/113 ,  A01K2267/0331 ,  A61K31/711 ,  A61K31/713 ,  A61K48/00 ,  C12N15/1137 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/3525 ,  C12N2310/3521

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of kinesin-like 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding kinesin-like 1. Methods of using these compounds for modulation of kinesin-like 1 expression and for treatment of diseases associated with expression of kinesin-like 1 are provided.

Abstract translation: 提供反义化合物，组合物和方法用于调节驱动蛋白样1的表达。组合物包含靶向编码驱动蛋白样物质的核酸的反义化合物，特别是反义寡核苷酸1.使用这些化合物调节驱动蛋白样1 提供表达和用于治疗与驱动蛋白样1的表达相关的疾病。

公开(公告)号：WO2005040180A3

公开(公告)日：2005-10-20

申请号：PCT/US2004031673

申请日：2004-09-27

Applicant: ISIS PHARMACEUTICALS INC ,  LUDWIG INST CANCER RES ,  CT FOR NEUROLOGIC STUDY ,  BENNETT FRANK C ,  DOBIE KENNETH W ,  CLEVELAND DON W ,  SMITH RICHARD ALAN ,  CONDON THOMAS P ,  JAIN RAVI ,  FREIER SUSAN M

Inventor： BENNETT FRANK C ,  DOBIE KENNETH W ,  CLEVELAND DON W ,  SMITH RICHARD ALAN ,  CONDON THOMAS P ,  JAIN RAVI ,  FREIER SUSAN M

IPC: A61K38/00 ,  C07H20060101 ,  C07H21/04 ,  C12N15/113 ,  C12Q1/68

CPC classification number: C12N15/1137 ,  A61K38/00 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12Y115/01001 ,  Y02P20/582 ,  C12N2310/3525

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase, soluble (SOD-1). The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding SOD-l. Methods of using these compounds for modulation of SOD-1 expression and for treatment of diseases associated with expression of SOD-1 are provided.

Abstract translation: 提供反义化合物，组合物和方法用于调节超氧化物歧化酶，可溶性（SOD-1）的表达。 该组合物包含靶向编码SOD-1的核酸的反义化合物，特别是反义寡核苷酸。 提供了使用这些化合物调节SOD-1表达和治疗与SOD-1表达相关的疾病的方法。

公开(公告)号：WO2004048522A3

公开(公告)日：2005-03-31

申请号：PCT/US0337345

申请日：2003-11-21

Applicant: ISIS PHARMACEUTICALS INC ,  BENNETT FRANK C ,  DEAN NICHOLAS M ,  DOBIE KENNETH W

Inventor： BENNETT FRANK C ,  DEAN NICHOLAS M ,  DOBIE KENNETH W

IPC: A01N43/04 ,  A61K48/00 ,  C07H21/02 ,  C07H21/04 ,  C12N20060101 ,  C12N15/88 ,  C12P19/34 ,  C12Q1/68

CPC classification number: C07H21/04 ,  A61K48/00

Abstract: Compounds, compositions and methods are provided for modulating the expression of huntingtin interacting protein 2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding huntingtin interacting protein 2. Methods of using these compounds for modulation of huntingtin interacting protein 2 expression and for diagnosis and treatment of disease associated with expression of huntingtin interacting protein 2 are provided.

Abstract translation: 提供化合物，组合物和方法用于调节亨廷丁蛋白相互作用蛋白2的表达。该组合物包含靶向编码亨廷顿蛋白相互作用蛋白的核酸的寡核苷酸2.使用这些化合物调节亨廷顿蛋白相互作用的蛋白2表达和用于诊断和治疗的方法 提供了与亨廷顿蛋白相互作用蛋白2的表达相关的疾病。

公开(公告)号：WO2004048325A3

公开(公告)日：2005-03-31

申请号：PCT/US0337756

申请日：2003-11-21

Applicant: ISIS PHARMACEUTICALS INC ,  DEAN NICHOLAS M ,  BENNETT FRANK C ,  DOBIE KENNETH W

Inventor： DEAN NICHOLAS M ,  BENNETT FRANK C ,  DOBIE KENNETH W

IPC: A61K38/00 ,  A61K48/00 ,  C12N5/02 ,  C12N15/113 ,  C12Q1/68 ,  A01N43/04 ,  A61K31/07 ,  C07H21/04

CPC classification number: C12N15/1138 ,  A61K38/00 ,  A61K48/00 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12Q1/6811 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/16 ,  C12N2310/3525

Abstract: Compounds, compositions and methods are provided for modulating the expression of jagged 1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding jagged 1. Methods of using these compounds for modulation of jagged 1 expression and for diagnosis and treatment of disease associated with expression of jagged 1 are provided.

Abstract translation: 提供化合物，组合物和方法用于调节锯齿状1的表达。组合物包含针对编码锯齿状的核酸的寡核苷酸1.使用这些化合物调节锯齿状1表达并用于诊断和治疗与表达相关的疾病 提供锯齿状1。

公开(公告)号：WO2004031350A3

公开(公告)日：2005-03-03

申请号：PCT/US0330352

申请日：2003-09-25

Applicant: AMGEN INC ,  ISIS PHARMACEUTICALS INC ,  DOBIE KENNETH W ,  BHANOT SANJAY ,  VENIANT-ELLISON MURIELLE ,  LINDBERG RICHARD A ,  SHUTTER JOHN R

Inventor： DOBIE KENNETH W ,  BHANOT SANJAY ,  VENIANT-ELLISON MURIELLE ,  LINDBERG RICHARD A ,  SHUTTER JOHN R

IPC: A61K38/00 ,  C12N15/113 ,  C12Q1/68 ,  A01N43/04 ,  A61K31/70 ,  C07H21/04 ,  C12N5/00

CPC classification number: C12N15/113 ,  A61K38/00 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  Y02P20/582 ,  C12N2310/3525

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particulary antisense oligonucleotides, targeted to nucleid acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.

Abstract translation: 提供反义化合物，组合物和方法用于调节叉头盒O1A的表达。 组合物包含靶向编码叉头盒O1A的核酸的反义化合物，特异性反义寡核苷酸。 提供使用这些化合物调节叉头盒O1A表达和治疗与叉头盒O1A表达有关的疾病的方法，特别是用于治疗糖尿病的方法。